
Lauren Sciences LLC Profile last edited on: 3/15/2023
CAGE: 6HTA4
UEI: Z9REXXRSNLX8
Business Identifier: Solving greatest medical challenge in treatment of central nervous system (CNS) diseases Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Single
Congr. District: 12
County: New York
Congr. District: 12
County: New York
Public Profile
Well funded from the early days after founding the firm by a range of sources to continue their work, Lauren Sciences is structured around addressing the medical challenge in treatment of central nervous system (CNS) diseases that most therapeutic agents, including biologicals, with potential to treat or cure brain diseases, do not cross blood brain barrier (BBB). V-Smart® Platform, breakthrough innovation, winning trifecta for brain delivery, enables non-invasive, triple-targeted CNS delivery of non-BBB penetrant therapeutic agents (nucleic acids, antibodies, biologics, small molecules, etc.). V-Smart® Pipeline includes V-Smart® Nanomedicines in development for CNS indications (ALS, PD, AD, Neuro-HIV, GBM, Chronic Pain, etc.). V-Smart® Nanomedicines for Pharma are in development with pharmaceutical companies proprietary therapeutic agents under confidentiality. V-Smart® Nanomedicines will significantly improve patients lives, as they enable patients to benefit from therapeutic agents whose use is currently unavailable due to BBB, PK, bioavailability or toxicity, long term invasive treatment, or where oral administration is preferable.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
10-14Revenue Range
1M-1.5MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
N/AAwards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2022 | 1 | NIH | $599,979 | |
Project Title: LAUR-201 (V-Smart®-TNV for Neuro-HIV): Novel V-Smart® Nanomedicine for Treatment of HAND |
Key People / Management
Susan Rosenbaum -- Founder, Chairman & Chief Executive Officer
Sarin Grinberg -- Director of Chemistry
Eliahu Heldman -- Director of Biology: Chief Scientific Officer
Irwin Hollander -- Vice President Research & Development
Charles Linder -- Director of Biophysics
Sarin Grinberg -- Director of Chemistry
Eliahu Heldman -- Director of Biology: Chief Scientific Officer
Irwin Hollander -- Vice President Research & Development
Charles Linder -- Director of Biophysics
Company News
There are no news available.